Salman Ghiasuddin, MD
Interventional Cardiology · Newburyport, MANPI 1467446120
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,974 of the $13,624 with a category attached, or 65.9%. It is spread thinly across 31 manufacturers, the largest accounting for just 18.6%. Reporting peaked in 2019 at $3,535 and has fallen 77.0% since, to $813 in 2025.
Across 371 payments — averaging $36.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Penumbra, Inc.$2K
- Pfizer$2K
- Boston Scientific$1K
- Cardiovascular Systems Inc.$811
- E.r. Squibb & Sons, L.L.C.$735
- plus $5K from 25 others
What the payments were for
- Travel & lodging$4,62834%
- Food & beverage$8,97466%
- Education$220%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 23 | $2,541 |
| Penumbra, Inc. | 6 | $2,027 |
| Pfizer | 69 | $1,549 |
| Boston Scientific | 11 | $1,440 |
| Cardiovascular Systems Inc. | 5 | $811 |
| E.r. Squibb & Sons, L.L.C. | 39 | $735 |
| Novartis | 42 | $659 |
| Johnson & Johnson | 36 | $629 |
| AstraZeneca | 29 | $604 |
| Amgen | 23 | $572 |
| Boehringer Ingelheim | 19 | $533 |
| Novo Nordisk | 10 | $227 |
| Merck | 11 | $204 |
| Heartflow, Inc. | 4 | $124 |
| Edwards Lifesciences | 1 | $124 |
| Esperion Therapeutics, Inc. | 6 | $110 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $109 |
| Abbott | 5 | $90 |
| Kiniksa Pharmaceuticals, Ltd. | 4 | $88 |
| Lexicon Pharmaceuticals, Inc. | 3 | $61 |
| Actelion Pharmaceuticals US, Inc. | 4 | $56 |
| Baxter Healthcare | 2 | $52 |
| Sanofi-aventis U.S. LLC | 2 | $47 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $47 |
| CMP Pharma, Inc. | 2 | $40 |
| Kowa Pharmaceuticals America, Inc. | 2 | $30 |
| Recor Medical Inc | 1 | $28 |
| Biotronik Inc. | 1 | $27 |
| Cvrx, Inc. | 1 | $24 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| Philips North America LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CoreValve Evolut$1,899
- RUBY Coil$1,868
- ANGIOJET$1,199
- Coronary Orbital Atherectomy System$641
- SAPIEN 3 Ultra RESILIA$124
- Indigo$106
- JARDIANCE$101
How this compares
$13,624 in reported general payments places this provider in the 65th percentile of 128 interventional cardiology providers in Massachusetts.
See all interventional cardiology providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 782 | $901,032 |
| XareltoRivaroxaban | 233 | $274,731 |
| Repatha SureclickEvolocumab | 67 | $71,013 |
| EntrestoSacubitril/Valsartan | 39 | $57,769 |
| JardianceEmpagliflozin | 57 | $38,020 |
| Praluent PenAlirocumab | 36 | $31,842 |
| BrilintaTicagrelor | 13 | $14,457 |
| Metoprolol Succinate | 648 | $11,063 |
| FarxigaDapagliflozin Propanediol | 12 | $10,545 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 557 | $9,832 |
| Rosuvastatin Calcium | 291 | $8,506 |
| Atorvastatin Calcium | 520 | $7,561 |
| Ezetimibe | 160 | $5,961 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 140 | $5,389 |
| Enoxaparin Sodium | 129 | $5,320 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $1,549 | $901,032782 claims |
| Johnson & JohnsonXarelto | $629 | $274,731233 claims |
| NovartisEntresto | $659 | $57,76939 claims |
| Boehringer IngelheimJardiance | $533 | $38,02057 claims |
| AstraZenecaBrilinta, Farxiga | $604 | $25,00225 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 128 interventional cardiology providers in Massachusetts.
Other interventional cardiology in Newburyport
- Eric SecemskyBoston$1.2M
- Darshan DoshiBoston$730K
- Charles GibsonBoston$661K
- Duane PintoBoston$491K
- Robert YehBoston$412K
- Thomas PiemonteBurlington$330K
- Suzanne BaronBoston$274K
- Farouc JafferBoston$213K
- Joseph GarasicBoston$152K
- Sergio WaxmanBurlington$148K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.